Challenges in GPCR Drug Design

Thijs Beuming (Latham BioPharm Group)
Zara Sands (Confo Therapeutics)
Javier Vázquez (Pharmacelera)

With around 35% of approved drugs targeting 108 members of GPCRs, this protein family is probably one of the most interesting and challenging targets when designing new drugs that modulate the downstream processes regulated by these proteins.

This new session of PharmWebinars intends to show which are the current challenges and state-of-the-art computational approaches in this area. We have invited three excelent speakers to share how the face the design of new drugs against these complex systems and the challenges they encounter.




Torre R, 4a planta, Despatx A05, Parc Científic de Barcelona (PCB). C/ Baldiri Reixac 4-8 08028 Barcelona